Keros Therapeutics (NASDAQ:KROS - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($1.14) earnings per share for the quarter, beating analysts' consensus estimates of ($1.36) by $0.22, Zacks reports. The business had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%.
Keros Therapeutics Stock Performance
Shares of NASDAQ KROS traded up $0.07 during trading on Friday, hitting $11.08. 2,027,042 shares of the company traded hands, compared to its average volume of 1,624,140. The firm has a market capitalization of $448.82 million, a price-to-earnings ratio of -2.13 and a beta of 1.39. The business's fifty day moving average is $12.52 and its 200 day moving average is $39.49. Keros Therapeutics has a fifty-two week low of $9.77 and a fifty-two week high of $73.00.
Wall Street Analyst Weigh In
KROS has been the subject of several recent research reports. Guggenheim reissued a "neutral" rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Oppenheimer decreased their target price on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a research report on Thursday, January 16th. William Blair lowered shares of Keros Therapeutics from an "outperform" rating to a "market perform" rating in a report on Thursday, December 12th. Jefferies Financial Group began coverage on shares of Keros Therapeutics in a research note on Tuesday, November 5th. They issued a "buy" rating on the stock. Finally, Wells Fargo & Company lowered their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, Keros Therapeutics has an average rating of "Moderate Buy" and an average target price of $42.33.
View Our Latest Research Report on Keros Therapeutics
Keros Therapeutics Company Profile
(
Get Free Report)
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Further Reading
Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
